The values and limits of an in vitro model of Pompe disease: The best laid schemes o’ mice an’ men ……..<sup>†</sup>
Shoichi Takikita(National Institutes of Health), Paul H. Plötz(National Institutes of Health), Nina Raben(APT Therapeutics (United States)), Rebecca Baum(National Institutes of Health), Cynthia Schreiner(National Institutes of Health), Rachel Myerowitz(National Institutes of Health)
Cited by 16
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395